Ibrahim Yalcin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ibrahim Yalcin has a total of 160 co-authors. Here are the top co-authors by number of shared publications:
- Ali Ayhan
School of Medicine, Department of Obstetrics and Gynecology, Başkent University, Bahçelievler, Ankara, Turkey
7 shared publications - Hanifi Sahin
Istanbul Health and Technology University, Istanbul, Türkiye
6 shared publications - Mehmet Mutlu Meydanli
Department of Gynecologic Oncology, Zekai Tahir Burak Women’s Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey
6 shared publications - Mustafa Erkan Sari
Department of Gynecologic Oncology, Zekai Tahir Burak Women's Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
6 shared publications - Tayfun Güngör
Department of Stem Cell Transplantation, University Children's Hospital, Zürich, Switzerland
4 shared publications - Asuman Nihan Haberal
Department of Pathology Başkent University Hospital Ankara Turkey
2 shared publications
Latest Publications
- 25 June 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- p. 104843
Uterovaginal Prolapse Complicating Gynecologic Cancer Management
- 25 June 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- p. 104843
Uterovaginal Prolapse Complicating Gynecologic Cancer Management
- 21 March 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (11) , 104649
Torsion of a borderline ovarian tumor in a pregnancy
- 21 March 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (11) , 104649
Torsion of a borderline ovarian tumor in a pregnancy
- Open Access
- 12 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (24) , 8807
Retrospective Multicenter Analysis of Malignant Struma Ovarii: Clinical Characteristics, Management, and Outcomes
Background/objectives: The study aimed to present cases of malignant struma ovarii from seven centers in Türkiye and evaluate them within the context of the existing literature. Methods: We retrospectively analyzed clinical data from 17 patients treated at seven centers, focusing on clinical features, surgical management, pathology, thyroid function, adjuvant treatment, and outcomes. Additionally, a literature review including eight studies with 178 patients was conducted. Results: The mean age of patients was 44.7 years, with a mean tumor size of 9.2 cm. Elevated Ca 125 was found in 33.3% of patients, while thyroid function abnormalities and hyperthyroidism signs were rare. Pelvic pain and menstrual irregularities were common presenting symptoms. A total of 16 patients (94.1%) had unilateral tumors. Total abdominal hysterectomy with bilateral salpingo-oophorectomy and unilateral salpingo-oophorectomy were the most frequent surgical approaches. Histopathology predominantly showed classical papillary thyroid carcinoma (13 patients, 76%). All patients were FIGO stage I, with no metastasis. Thyroidectomy was performed in seven patients, identifying two concurrent thyroid cancers. Four patients received adjuvant radioactive iodine therapy. During a median follow-up of 43 months, no deaths and one recurrence were observed. The literature review showed a diagnosis age ranging 43–53 years and papillary thyroid carcinoma as the most common subtype. Thyroidectomy and RAI treatment were selectively applied. Among the reported studies, recurrence occurred in 7 of 76 patients (9.2%), while 5-year disease-free and overall survival rates exceeded 94% and 100%, respectively. BRAF mutations were uncommon. Conclusions: Malignant struma ovarii is a rare tumor with a favorable prognosis when diagnosed early and managed appropriately.
- 12 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (24) , 8807
Open AccessRetrospective Multicenter Analysis of Malignant Struma Ovarii: Clinical Characteristics, Management, and Outcomes
Background/objectives: The study aimed to present cases of malignant struma ovarii from seven centers in Türkiye and evaluate them within the context of the existing literature. Methods: We retrospectively analyzed clinical data from 17 patients treated at seven centers, focusing on clinical features, surgical management, pathology, thyroid function, adjuvant treatment, and outcomes. Additionally, a literature review including eight studies with 178 patients was conducted. Results: The mean age of patients was 44.7 years, with a mean tumor size of 9.2 cm. Elevated Ca 125 was found in 33.3% of patients, while thyroid function abnormalities and hyperthyroidism signs were rare. Pelvic pain and menstrual irregularities were common presenting symptoms. A total of 16 patients (94.1%) had unilateral tumors. Total abdominal hysterectomy with bilateral salpingo-oophorectomy and unilateral salpingo-oophorectomy were the most frequent surgical approaches. Histopathology predominantly showed classical papillary thyroid carcinoma (13 patients, 76%). All patients were FIGO stage I, with no metastasis. Thyroidectomy was performed in seven patients, identifying two concurrent thyroid cancers. Four patients received adjuvant radioactive iodine therapy. During a median follow-up of 43 months, no deaths and one recurrence were observed. The literature review showed a diagnosis age ranging 43–53 years and papillary thyroid carcinoma as the most common subtype. Thyroidectomy and RAI treatment were selectively applied. Among the reported studies, recurrence occurred in 7 of 76 patients (9.2%), while 5-year disease-free and overall survival rates exceeded 94% and 100%, respectively. BRAF mutations were uncommon. Conclusions: Malignant struma ovarii is a rare tumor with a favorable prognosis when diagnosed early and managed appropriately.
- 14 October 2025
- Published by Springer Nature in Reproductive Sciences
- Vol. 32 (11) , 3539-3545
Challenges in Fertility Preservation for p53abn Grade 2 Endometrioid Endometrial Cancer: A Case Report and Literature Review
Endometrial carcinoma, the second most common gynecological cancer, is increasingly affecting younger women, particularly due to rising obesity rates. The need for precise molecular tools is paramount for better categorization and risk stratification, especially in fertility preservation, as current methods often fall short. Fertility preservation is considered for early-stage, nonmetastatic cases, but the role of molecular classifications in this area remains underexplored. We present the case of a 35-year-old woman with grade 2 p53abn endometrioid endometrial cancer who sought fertility preservation. Her initial treatment involved hysteroscopy-guided resection, hormonal therapy with megestrol acetate (MA), and close monitoring, but the disease recurred within six months. A literature review reveals that fertility preservation in p53abn endometrial carcinoma is poorly documented, with variable outcomes. Many cases indicate a poor response to progestin therapy and a heightened risk of recurrence, highlighting the need for personalized treatment approaches. Additionally, our case identifies “a novel PTEN somatic mutation (Tier 2C)” that has not been previously reported in endometrial cancer. This case underscores the essential role of molecular profiling in clinical decision-making and the need for ongoing research into molecular pathways. Integrating molecular classifiers into routine practice is crucial for improving risk stratification and treatment outcomes, especially in young women pursuing fertility preservation.
- 14 October 2025
- Published by Springer Nature in Reproductive Sciences
- Vol. 32 (11) , 3539-3545
Challenges in Fertility Preservation for p53abn Grade 2 Endometrioid Endometrial Cancer: A Case Report and Literature Review
Endometrial carcinoma, the second most common gynecological cancer, is increasingly affecting younger women, particularly due to rising obesity rates. The need for precise molecular tools is paramount for better categorization and risk stratification, especially in fertility preservation, as current methods often fall short. Fertility preservation is considered for early-stage, nonmetastatic cases, but the role of molecular classifications in this area remains underexplored. We present the case of a 35-year-old woman with grade 2 p53abn endometrioid endometrial cancer who sought fertility preservation. Her initial treatment involved hysteroscopy-guided resection, hormonal therapy with megestrol acetate (MA), and close monitoring, but the disease recurred within six months. A literature review reveals that fertility preservation in p53abn endometrial carcinoma is poorly documented, with variable outcomes. Many cases indicate a poor response to progestin therapy and a heightened risk of recurrence, highlighting the need for personalized treatment approaches. Additionally, our case identifies “a novel PTEN somatic mutation (Tier 2C)” that has not been previously reported in endometrial cancer. This case underscores the essential role of molecular profiling in clinical decision-making and the need for ongoing research into molecular pathways. Integrating molecular classifiers into routine practice is crucial for improving risk stratification and treatment outcomes, especially in young women pursuing fertility preservation.
- 15 March 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (5) , 101771
Sentinel SENECA risk factors for unsuccessful bi-lateral sentinel lymph node mapping in endometrial cancer
- 15 March 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (5) , 101771
Sentinel SENECA risk factors for unsuccessful bi-lateral sentinel lymph node mapping in endometrial cancer
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Sao Paulo Medical Journal
- Vol. 143 (6) , e20252881
Prognostic value of chemotherapy response score in advanced ovarian cancer: a single-center retrospective analysis
BACKGROUND: The chemotherapy response score (CRS) is a histopathological tool used to assess the tumor response in patients with high-grade serous ovarian carcinoma (HGSC) undergoing neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS). DESIGN AND SETTING: This single-center retrospective study was conducted at the Faculty of Medicine at Istanbul University. The study included patients treated between January 1, 2010, and December 31, 2017 at a tertiary care hospital specializing in gynecologic oncology. OBJECTIVES: This study aimed to evaluate the prognostic significance of omental and adnexal CRS in predicting overall survival (OS) and disease-free survival (DFS) in patients with advanced HGSC undergoing NACT followed by IDS. METHODS: Data from 79 patients with advanced HGSC treated with NACT followed by IDS between 2010 and 2017 were analyzed. CRS was applied to both omental and adnexal samples, and its association with OS and DFS was evaluated. Statistical analyses were performed using univariate and multivariate methods with a significance level of P < 0.05. RESULTS: Omental CRS 1-2 was identified as an independent predictor of decreased OS (hazard ratio 2.69; 95% confidence interval 1.26–5.76, P = 0.010), whereas adnexal CRS 1-2 did not significantly impact DFS or OS in multivariate analysis. Patients with omental CRS 3 had superior outcomes, with a 5-year OS rate of 72%, compared to 30.8% in the CRS 1–2 group. The median DFS of the CRS 1–2 group was 19 months, whereas that of the CRS 3 group was 35 months (P = 0.005). CONCLUSIONS: Omental CRS is a strong independent predictor of OS in patients with advanced HGSC, whereas adnexal CRS has limited prognostic value. CRS should be considered in clinical practice to guide treatment decisions, and further research is warranted to refine its use by using molecular and radiological markers.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Sao Paulo Medical Journal
- Vol. 143 (6) , e20252881
Open AccessPrognostic value of chemotherapy response score in advanced ovarian cancer: a single-center retrospective analysis
BACKGROUND: The chemotherapy response score (CRS) is a histopathological tool used to assess the tumor response in patients with high-grade serous ovarian carcinoma (HGSC) undergoing neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS). DESIGN AND SETTING: This single-center retrospective study was conducted at the Faculty of Medicine at Istanbul University. The study included patients treated between January 1, 2010, and December 31, 2017 at a tertiary care hospital specializing in gynecologic oncology. OBJECTIVES: This study aimed to evaluate the prognostic significance of omental and adnexal CRS in predicting overall survival (OS) and disease-free survival (DFS) in patients with advanced HGSC undergoing NACT followed by IDS. METHODS: Data from 79 patients with advanced HGSC treated with NACT followed by IDS between 2010 and 2017 were analyzed. CRS was applied to both omental and adnexal samples, and its association with OS and DFS was evaluated. Statistical analyses were performed using univariate and multivariate methods with a significance level of P < 0.05. RESULTS: Omental CRS 1-2 was identified as an independent predictor of decreased OS (hazard ratio 2.69; 95% confidence interval 1.26–5.76, P = 0.010), whereas adnexal CRS 1-2 did not significantly impact DFS or OS in multivariate analysis. Patients with omental CRS 3 had superior outcomes, with a 5-year OS rate of 72%, compared to 30.8% in the CRS 1–2 group. The median DFS of the CRS 1–2 group was 19 months, whereas that of the CRS 3 group was 35 months (P = 0.005). CONCLUSIONS: Omental CRS is a strong independent predictor of OS in patients with advanced HGSC, whereas adnexal CRS has limited prognostic value. CRS should be considered in clinical practice to guide treatment decisions, and further research is warranted to refine its use by using molecular and radiological markers.
- 31 December 2024
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (1) , 100041
Risk factors for the involvement of sentinel lymph nodes in endometrial cancer (TRSGO-SLN-010)
- 31 December 2024
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (1) , 100041
Risk factors for the involvement of sentinel lymph nodes in endometrial cancer (TRSGO-SLN-010)
- Open Access
- 26 December 2023
- Published by IMR Press in Clinical and Experimental Obstetrics & Gynecology
- Vol. 50 (12) , 270
Prognostic Role of Lymphadenectomy among Women with Low Grade Lymphovascular Space Invasion-Positive Clinically Uterus Confined Endometrioid Endometrial Cancer
Background: Possible therapeutic benefits of lymphadenectomy (LND) in the treatment of endometrial cancer (EC) remain controversial. The present study was undertaken with the aim of investigating the prognostic role of LND in women with clinically confirmed, low-grade, uterus-confined endometrioid EC exhibiting lymphovascular space invasion. Methods: A bicentric retrospective review was conducted for the identification of cases of EC, treated at two gynecologic oncology departments in Turkey. Subsequently, the data of 1811 patients with EC (non-endometrioid, endometrioid, or mixed histology) who had undergone surgery between 2007 and 2016 were analyzed. After extracting data, 37 patients were defined as the study group, and those 37 cases were matched to 74 control patients who had undergone surgery with systematic LND to compare survival. Kaplan-Meier analysis was applied in the process of interpreting data on survival, and variables predicting patient outcomes were identified using Cox proportional hazards regression. Results: Five-year disease-free survival (DFS) rates were 88.2% versus 81.5% (p = 0.985), while overall survival (OS) rates were 91.0% versus 85.7% (p = 0.814) for the study and control groups, respectively. Advanced ages (hazard ratio (HR): 6.69; 95% confidence interval (CI): 1.59–28.09, p = 0.009) and tumors of grade 2 (HR: 3.35; 95% CI: 1.09–10.26, p = 0.034) were found to be independently predictive of decreased OS within the entire cohort. Conclusions: Systematic LND does not have a therapeutic role in the management of low-grade, uterus-confined endometrioid EC with lymphovascular space invasion. There was no difference between the survival outcomes of the two groups considered in this study.
- 26 December 2023
- Published by IMR Press in Clinical and Experimental Obstetrics & Gynecology
- Vol. 50 (12) , 270
Open AccessPrognostic Role of Lymphadenectomy among Women with Low Grade Lymphovascular Space Invasion-Positive Clinically Uterus Confined Endometrioid Endometrial Cancer
Background: Possible therapeutic benefits of lymphadenectomy (LND) in the treatment of endometrial cancer (EC) remain controversial. The present study was undertaken with the aim of investigating the prognostic role of LND in women with clinically confirmed, low-grade, uterus-confined endometrioid EC exhibiting lymphovascular space invasion. Methods: A bicentric retrospective review was conducted for the identification of cases of EC, treated at two gynecologic oncology departments in Turkey. Subsequently, the data of 1811 patients with EC (non-endometrioid, endometrioid, or mixed histology) who had undergone surgery between 2007 and 2016 were analyzed. After extracting data, 37 patients were defined as the study group, and those 37 cases were matched to 74 control patients who had undergone surgery with systematic LND to compare survival. Kaplan-Meier analysis was applied in the process of interpreting data on survival, and variables predicting patient outcomes were identified using Cox proportional hazards regression. Results: Five-year disease-free survival (DFS) rates were 88.2% versus 81.5% (p = 0.985), while overall survival (OS) rates were 91.0% versus 85.7% (p = 0.814) for the study and control groups, respectively. Advanced ages (hazard ratio (HR): 6.69; 95% confidence interval (CI): 1.59–28.09, p = 0.009) and tumors of grade 2 (HR: 3.35; 95% CI: 1.09–10.26, p = 0.034) were found to be independently predictive of decreased OS within the entire cohort. Conclusions: Systematic LND does not have a therapeutic role in the management of low-grade, uterus-confined endometrioid EC with lymphovascular space invasion. There was no difference between the survival outcomes of the two groups considered in this study.